Analysis of the prevalence and risk factors of osteoarthritis in a population

Portyannikova, O.O.; Tsvinger, S. M.; Говорин, А. В.; Romanova, E. Yu.

doi:10.14412/1996-7012-2019-2-105-111

Cited by 14 publications

(2 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite many research advances, the etiology and pathogenesis of OA are still unclear. The main causes of OA include age, obesity, genetics, endocrine and metabolic illnesses, inflammation, trauma, and the combined influence of various factors 13–15 . A deeper comprehension of the OA's pathogenic mechanisms will encourage the identification of new treatment targets to slow the disease progression (Figure 2).…”

Section: Pathogenesis Of Oa and Clinical Treatmentmentioning

confidence: 99%

Functional biomaterials for osteoarthritis treatment: From research to application

et al. 2022

View full text Add to dashboard Cite

Osteoarthritis (OA) is a common disease that endangers millions of middle‐aged and elderly people worldwide. Researchers from different fields have made great efforts and achieved remarkable progress in the pathogenesis and treatment of OA. However, there is still no cure for OA. In this review, we discuss the pathogenesis of OA and summarize the current clinical therapies. Moreover, we introduce various natural and synthetic biomaterials for drug release, cartilage transplantation, and joint lubricant during the OA treatment. We also present our perspectives and insights on OA treatment in the future. We hope that this review will foster communication and collaboration among biological, clinical, and biomaterial researchers, paving the way for OA therapeutic breakthroughs.

show abstract

Section: Pathogenesis Of Oa and Clinical Treatmentmentioning

confidence: 99%

Functional biomaterials for osteoarthritis treatment: From research to application

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Osteoarthritis (OA) is the most common disease affecting more than 300 million people worldwide [1][2][3]. In the Russian Federation, OA is diagnosed in about 4% of the adult population, most often − in subjects over 60 years of age, and in recent years there has been a trend towards an increase in incidence of disease among the adult population [4][5][6]. One of the most common location of the disease is the knee joint.…”

Section: Introductionmentioning

confidence: 99%

Validity of Knee Arthroplasty in Osteoarthritis

EV¹,

AN²,

RV³

et al. 2023

Act Scie Ortho

View full text Add to dashboard Cite

Introduction and Materials and Methods:In the clinic of orthopedics and trauma North-western State Medical University named after I.I. Mechnikov from 01.01.2022 to 15.12.2022, a total of 187 total knee replacement (TKR) were done in patients with osteoarthritis. A random sample taken for histological studies from 30 patients aged 40 to 76 years (19 F, 11 M). Samples were prepared according to the standard protocol for bone tissue, the bone fragments tested were decalcified in electrolyte decalcification solution (Biovitrum, Russia). Histological processing, pouring, and microtomy with a section thickness of 5 μm were performed as per standard protocol. The preparations were stained with dyes (hematoxylin and eosin) and safranin O.Results: Only 48 (25.7%) patients before TKR were at least once had inpatient conservative or minimally invasive surgical treatment for osteoarthritis of the knee joint. 18 (9.6%) patients had intraoperative and postoperative complications. Among the 30 morphological studies performed, 3 (10%) patients grade I, 8 (26.7%) subjects grade II, and in 19 (63.3%) -grade III osteoarthritis of the knee joint was diagnosed.Conclusions: Among patients who underwent TKR, only one in four (48 people -25.7%) was at least once had inpatient conservative or minimally invasive surgical treatment for OA. According to the morphological study, 11 (36.7%) clinical observations undergoing arthroplasty were verified as grade I-II OA. To form a strategy for the treatment of patients with osteoarthritis of knee joint, it is vital to develop an algorithm for teamwork between therapist, orthopedic surgeon, rheumatologist, rehabilitation medicine specialist, specialists in restorative medicine and healthcare organizers in the process.Such results are given by russian scientists. In 2019, A.V. Lychagin., et al. studied the validity of TKR in elderly patients. The

show abstract

Chondroitin sulfate in osteoarthritis treatment in patients with comorbid cardiovascular diseases: hypertension, atherosclerosis, coronary heart disease

Shavlovskaya

Бокова

Сарвилина³

et al. 2021

RJTAO

View full text Add to dashboard Cite

Osteoarthritis (OA) is the most common joint disease globally, and its incidence increases with age – up to 80–90% in people over 60 years. There is a high comorbidity between OA and cardiovascular diseases (CVD), such as arterial hypertension (AH), atherosclerosis, and coronary heart disease (CHD). The main objectives of OA therapy include pain reduction, cartilage matrix preservation, safe profile in patients with comorbid diseases, minimal adverse effects. In addition, the drug should be comparable in analgesic effects with nonsteroidal anti-inflammatory drugs (NSAIDs). Such drugs include structural-modifying agents – symptomatic slow-acting drugs for osteoarthritis (SYSADOA), one of which is chondroitin sulfate (CS). According to the 2019–2020 International and Russian guidelines, only pharmaceutical-grade CS is recommended for use. The high efficacy of intramuscular administration of CS in patients with OA, lower back pain, and comorbid diseases (AH, CHD, atherosclerosis) has been proven. CS is prescribed for a long treatment course – up to two months.

show abstract

Analysis of the prevalence and risk factors of osteoarthritis in a population

Cited by 14 publications

References 57 publications

Functional biomaterials for osteoarthritis treatment: From research to application

Functional biomaterials for osteoarthritis treatment: From research to application

Validity of Knee Arthroplasty in Osteoarthritis

Chondroitin sulfate in osteoarthritis treatment in patients with comorbid cardiovascular diseases: hypertension, atherosclerosis, coronary heart disease

Contact Info

Product

Resources

About